AL-S Pharma AG

AL-S Pharma is a Swiss biopharmaceutical company developing AP-101, a first-in-class human-derived monoclonal antibody targeting misfolded superoxide dismutase 1 (SOD1) for the treatment of amyotrophic lateral sclerosis. The single-asset company was founded by Neurimmune and TVM Capital Life Science and recently reported positive Phase 2 results supporting a confirmatory Phase 3 study.